Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | PYGL | P06737 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | THRA | P10827 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6631155 | 0.83 | MEN1 (0.46) | HRH3PYGLPOLBHDAC6 | |
| SCHEMBL14052828 | 0.83 | HRH3 (0.61) | CYP4F2CYP4A11CA2HRH3CNR1 | |
| SCHEMBL5789 | 0.82 | CYP4F2 (0.48) | CYP4F2CYP4A11CA2HRH3PYGL | |
| SCHEMBL6629816 | 0.80 | SMN1; SMN2 (0.57) | CYP4F2CYP4A11CA2TDP1CA12 | |
| SCHEMBL8867308 | 0.80 | PEPD (0.55) | CYP4F2CYP4A11CA2CA12CA1 | |
| SCHEMBL9566474 | 0.80 | SMN1; SMN2 (0.46) | CA2TDP1CA12CA1CA4 | |
| SCHEMBL8867209 | 0.79 | THRA (0.65) | CYP4F2CYP4A11THRATHRB | |
| SCHEMBL5539011 | 0.79 | POLB (0.66) | CA2THRATHRBCA12CA1 | |
| SCHEMBL8604610 | 0.78 | RXFP1 (0.56) | CYP4F2CYP4A11HRH3PYGLTHRA | |
| SCHEMBL5546223 | 0.78 | THRA (0.68) | CA2THRATHRBCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232875-A1 | Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors | ASTRAZENECA AB (SE) | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232875-A1 | Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors | GYS1, GYS2, PYGL | CYP4F2 943/4885CYP4A11 361/4885CA2 922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.